These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 35856431)
1. Conjoint analysis of OPRPN and SMR3A protein expression as potential predictive biomarkers for head and neck squamous cell carcinoma after radiotherapy. Rong C; Grünow J; Thierauf J; Lucena-Porcel C; Major G; Holzinger D; Dyckhoff G; Kern J; Lammert A; Scherl C; Rotter N; Plinkert PK; Affolter A Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35856431 [TBL] [Abstract][Full Text] [Related]
2. Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells. Grünow J; Rong C; Hischmann J; Zaoui K; Flechtenmacher C; Weber KJ; Plinkert P; Hess J J Exp Clin Cancer Res; 2017 Feb; 36(1):25. PubMed ID: 28166815 [TBL] [Abstract][Full Text] [Related]
3. Expression of Submaxillary Gland Androgen-regulated Protein 3A (SMR3A) in Adenoid Cystic Carcinoma of the Head and Neck. Thierauf J; Veit JA; Grünow J; Döscher J; Weißinger S; Whiteside T; Beutner D; Quaas A; Plinkert P; Hoffmann TK; Hess J Anticancer Res; 2016 Feb; 36(2):611-5. PubMed ID: 26851015 [TBL] [Abstract][Full Text] [Related]
4. Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery. Koffler J; Holzinger D; Sanhueza GA; Flechtenmacher C; Zaoui K; Lahrmann B; Grabe N; Plinkert PK; Hess J Eur Arch Otorhinolaryngol; 2013 Mar; 270(4):1493-500. PubMed ID: 23053383 [TBL] [Abstract][Full Text] [Related]
5. Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Schrader CH; Kolb M; Zaoui K; Flechtenmacher C; Grabe N; Weber KJ; Hielscher T; Plinkert PK; Hess J Mol Cancer; 2015 May; 14():107. PubMed ID: 25990935 [TBL] [Abstract][Full Text] [Related]
6. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy. Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886 [TBL] [Abstract][Full Text] [Related]
8. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582 [TBL] [Abstract][Full Text] [Related]
9. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. Bayo P; Jou A; Stenzinger A; Shao C; Gross M; Jensen A; Grabe N; Mende CH; Rados PV; Debus J; Weichert W; Plinkert PK; Lichter P; Freier K; Hess J Mol Oncol; 2015 Oct; 9(8):1704-19. PubMed ID: 26040981 [TBL] [Abstract][Full Text] [Related]
10. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Akervall J; Nandalur S; Zhang J; Qian CN; Goldstein N; Gyllerup P; Gardinger Y; Alm J; Lorenc K; Nilsson K; Resau J; Wilson G; Teh B Eur J Cancer; 2014 Feb; 50(3):570-81. PubMed ID: 24332450 [TBL] [Abstract][Full Text] [Related]
11. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017 [TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Freudlsperger C; Horn D; Weißfuß S; Weichert W; Weber KJ; Saure D; Sharma S; Dyckhoff G; Grabe N; Plinkert P; Hoffmann J; Freier K; Hess J Int J Cancer; 2015 Jun; 136(12):2775-85. PubMed ID: 25388642 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of WD repeat domain 5 associates with aggressive clinicopathological features and unfavorable prognosis in head neck squamous cell carcinoma. Wu Y; Diao P; Li Z; Zhang W; Wang D; Wang Y; Cheng J J Oral Pathol Med; 2018 May; 47(5):502-510. PubMed ID: 29569374 [TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma. Borgmann M; Oetting A; Meyer F; Möckelmann N; Droste C; von Bargen CM; Möller-Koop C; Witt M; Borgmann K; Rothkamm K; Betz C; Münscher A; Clauditz TS; Rieckmann T J Cancer Res Clin Oncol; 2023 Jul; 149(7):3383-3393. PubMed ID: 35941227 [TBL] [Abstract][Full Text] [Related]
15. Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma. Kreycy N; Gotzian C; Fleming T; Flechtenmacher C; Grabe N; Plinkert P; Hess J; Zaoui K BMC Cancer; 2017 May; 17(1):382. PubMed ID: 28549423 [TBL] [Abstract][Full Text] [Related]
16. Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome. Erben PB; Brunner K; Hecht M; Haderlein M; Büttner-Herold M; Agaimy A; Fietkau R; Hartmann A; Distel LV Int J Clin Exp Pathol; 2015; 8(12):15814-24. PubMed ID: 26884852 [TBL] [Abstract][Full Text] [Related]
17. Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas. Wong N; Khwaja SS; Baker CM; Gay HA; Thorstad WL; Daly MD; Lewis JS; Wang X Cancer Med; 2016 Jul; 5(7):1619-28. PubMed ID: 27109697 [TBL] [Abstract][Full Text] [Related]
18. Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Benaiges E; Ceperuelo-Mallafré V; Guaita S; Maymó-Masip E; Madeira A; Gómez D; Hernández V; Vilaseca I; Merma C; León X; Terra X; Vendrell J; Avilés-Jurado FX; Fernández-Veledo S Head Neck; 2024 Jul; 46(7):1752-1765. PubMed ID: 38305029 [TBL] [Abstract][Full Text] [Related]
19. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma. Li B; Zhu J; Meng L Mol Med Rep; 2019 Feb; 19(2):877-884. PubMed ID: 30535476 [TBL] [Abstract][Full Text] [Related]
20. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]